Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life
2011 ◽
Vol 17
(10)
◽
pp. 1490-1496
◽
2020 ◽
2013 ◽
Vol 19
(2)
◽
pp. S265-S266
2019 ◽
Vol 12
(8)
◽
pp. 575-578
◽
2017 ◽
Vol 93
(2)
◽
pp. 222-231
◽
2018 ◽
Vol 24
(3)
◽
pp. S79-S80
◽
2016 ◽
Vol 22
(3)
◽
pp. S359